This is a post that I submitted last night over in hell

New Post Public Reply Private Reply Replies (0) Message Board
patientgal
This is a post that I submitted last night over in hell that was subsequently deleted, of course. It was in response to someone saying that BP don't fund trials or jump aboard with biotechs until years into trials. I can't remember the full content of the post. But, that was the essence. Which, is a crock of BS:

This is a new day in new medicine and we haven't begun to really understand the potential. Well, some of us have an idea.


KOOS KNOWS WHAT HE IS DOING. AND ONE THING HE IS NOT DOING IS SELLING. BP OR VENTURE CAPITALISTS WILL BE ON BOARD LONG BEFORE ANYONE SUSPECTS. AND WHEN THEY DO, BUH BYE FLIPPERS!

BMSN

The feared “patent cliff” for brand-name drugs has caused billion-dollar blockbusters like Pfizer’s cholesterol drug Lipitor and Bristol-Myers Squibb’s blood thinner Plavix to lose ground to generic competition, so the pharmaceutical industry has been hunting for innovation among small biotechnology companies, as both takeover targets [u]and licensing partners[/u].

There were five acquisitions of [u]venture capital-backed biotech companies in the second quarter alone[/u], according to data from Thomson Reuters and the National Venture Capital Association.
“[u]I think the big pharma companies are going to continue to look outside to find the next wave of innovative therapies,” said Dennis Purcell, senior managing partner of Aisling Capital, a life sciences venture capital firm based in New York.[/u]

On June 17, an Aisling portfolio company in San Diego, [u]Aragon Pharmaceuticals, which has a prostate cancer treatment in midstage human trials, was bought by Johnson & Johnson for $650 million up front, plus the potential for an additional $350 million in payments tied to research milestones.[/u]
Still, biotechnology is more prone to disappointments than perhaps any other industry — a risk that came to light not long before this recent run of I.P.O.’s.

In May, shares of a former high flyer, Aveo Pharmaceuticals, fell nearly 50 percent when an advisory panel to the Food and Drug Administration urged the agency to reject the company’s kidney cancer drug because of questions about its efficacy.
That so many investors have been able to overlook such uncertainty and jump into a new class of companies with unproved science shows a new tolerance for risk on the public market, some experts say.

The robust deal-making environment helps.
“[u]People are hungry for growth,” said Erik Gordon, a professor specializing in life sciences entrepreneurship at the University of Michigan’s business school. “When you see something like Onyx telling Amgen” its offering price is too low, “you have to ask, what’s the downside? The downside is bad news, but if that doesn’t happen, the company you’ve invested in could be taken out at a huge gain.”[/u]The 16 biotechnology companies that have gone public this year are up 48 percent on average from their offering prices, according to data provided by Nasdaq.

As of Tuesday, four of the top 10 performing companies on the Nasdaq year-to-date were biotechs: Stemline Therapeutics, Bluebird Bio, Epizyme and Prosensa Holding.
“The fact that these companies can get out reloads the capacity of the venture funders” to turn to the public markets, said Samuel Isaly, managing partner of OrbiMed Advisors, which manages the Eaton Vance Worldwide Health Sciences Fund in addition to private equity and hedge funds. “We’re back to the good old days of before the financial crash.”The biotechnology I.P.O. market is so frothy, in fact, that some companies are not waiting to take advantage of it. Hans Schikan, the chief executive of the Dutch biotech company Prosensa, said he and his management team originally planned their I.P.O. for a week or so after the Fourth of July holiday, but when they saw the positive investor response to Epizyme and others, they rushed out on June 28 instead. “When the window’s open, you’d better use it,” Mr. Schikan said. Prosensa’s shares opened $7 above its $13 offering price and are up 102 percent so far. It closed up 1.1 percent in trading Thursday on the Nasdaq, closing at $26.26.One gateway for acquisitions in the biotech sector is research partnerships, and those are increasing as well.[u]Epizyme did not start human testing of its lead drug until late last year, but it attracted plenty of interest from big pharmaceutical companies long before that.

The company formed research partnerships with GlaxoSmithKline, Celgene and Eisai, which together were worth $125 million in nonequity financing.[/u]
Simos Simeonidis, an analyst at Cowen & Company, predicts that if one of Epizyme’s two leading cancer drugs shows even a hint of success in clinical trials, “a lot of big pharmas or big biotechs are going to want to own the platform. The possibility of an acquisition in my mind would be very high,” he said.

Several other members of this year’s biotech I.P.O. class have rich partnerships. [u]Bluebird Bio of Massachusetts signed a three-year oncology research deal with Celgene in March, which included a $75 million upfront payment. Bluebird’s I.P.O. was on June 19, and its stock has climbed 78 percent.[/u]PTC Therapeutics, a New Jersey company that went public the next day and raised $114 million, [u]has a $30 million deal with Roche to study treatments for spinal muscular atrophy, and an oncology partnership with AstraZeneca that included an undisclosed upfront payment.

Both deals included the potential for milestone bonuses. Its shares have risen 9 percent. On Thursday, they rose 3.4 percent to close at $16.34.[/u]
Robert J. Gould, the chief executive of Epizyme, said he was aware that research partnerships often blossomed into full-blown buyout offers. But “we have no intention of positioning ourselves to be acquired,” he said. Bluebird and PTC, both still in post-offering quiet periods, declined to comment.[u]Venture capitalists in life sciences predict that both the pace and the value of licensing deals will accelerate. “Pharma certainly is evaluating every single asset of every single company that’s out there and acting on it,” said Noubar Afeyan, managing partner and chief executive of Flagship Ventures, an investor in Agios Pharmaceuticals of Massachusetts, which announced its intention on June 10 to raise $86 million in an I.P.O. Agios has a $150 million cancer drug development deal with Celgene.[/u]

It is not just cancer treatment that is generating excitement among investors. Prosensa is developing drugs to treat Duchenne muscular dystrophy and other muscle disorders. PTC has its own treatment for muscular dystrophy and is also developing drugs to fight cystic fibrosis and infectious disease.

The one unifying theme in all the companies that have generated excitement on Wall Street is the rise of personalized medicine, said Christoph Westphal, a longtime biotechnology entrepreneur and a founder and partner of the Longwood Fund. “Many companies that have done well recently have a specific molecular-medicine approach to a serious disorder that has no other therapies,” he said.
Prosensa’s two lead drugs for muscular dystrophy, for example, are being tested in small groups of patients whose disease is caused by specific genetic mutations, which can be detected with diagnostic devices that the company is using with the drugs.

Another factor in the biotech industry’s favor is that regulators have [u]become more supportive of drugs that address high unmet medical needs. [/u]

In July 2012, the Food and Drug Administration Safety and Innovation Act established the “breakthrough therapy” designation, which gave the agency the authority to speed its review of drugs to treat life-threatening ailments.
“The regulators, notably the F.D.A., [u]have been particularly willing to come up with new strategies to enable the rapid development of drugs for which there is a dramatic effect in a defined patient population,” said Robert Tepper, a partner at Third Rock Ventures, an investor in both Bluebird and Agios.[/u]

“If you can stratify the patient population you want to treat through genetic analysis, for example, you can move quite quickly through early-stage trials.

RIVULET MEDIA INC. (RIVU) Stock Research Links

RIVU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 33

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Fermi Board Fight Tests Texas Governance Standards Again

Updated Category News Views 93

A boardroom rulebook is supposed to restrain power, not become a trapdoor under shareholders’ feet. That is the ugly governance question hanging over Fermi after the Texas Business Court dismissed Toby Neugebauer’s challenge to the company’s 70% supermajority bylaw. Neugebauer, Fermi’s co-founder and largest shareholder, says he will appeal. Frankly, he has every...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 72

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 91

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 97

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 51

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 45

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 158

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 68

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 70

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading

Top 5 Most Recently Viewed Articles

Analysis of Smart Stadium Market Dynamics and Trends

Updated Category News Views 100

Overview of the Smart Stadium Market Custom Market Insights has released an in-depth study on the Smart Stadium Market within its research database. This report sheds light on current market trends and insights, focusing on components like Software and Services, as well as applications such as Digital Content Management and Stadium and Public Security. In 2023, the market...

Continue Reading
Transforming $1000 in ProShares UltraPro QQQ: A Decade of Growth

Updated Category News Views 233

Transforming a $1000 Investment into a Small Fortune ProShares UltraPro QQQ (NASDAQ:TQQQ) has shown impressive performance in the stock market over the decade. Investors who placed their confidence in this fund have enjoyed remarkable annualized returns of 36.49%. This performance surpasses market averages by a significant margin, indicating a powerful investment choice...

Continue Reading
Trifork Group Reports Executive Transactions Announcing Shares

Updated Category News Views 217

Trifork Group's Recent Executive Transactions As part of its ongoing commitment to transparency, Trifork Group AG has reported significant transactions involving its executive team. These disclosures, in accordance with the Market Abuse Regulation Article 19, inform stakeholders about the exchange of fixed salaries for shares, a practice that aligns executive interests...

Continue Reading
Understanding Disclosure Requirements for Assura Plc's Shares

Updated Category News Views 178

Understanding Disclosure Requirements for Assura Plc's Shares Disclosures in the financial market are vital for transparency, especially for companies like Assura Plc. This article provides an insightful overview of the recent public opening position disclosures and relevant securities that attract attention in the market landscape. Key Details of the Disclosure The...

Continue Reading
The Importance of Kindness: Celebrating Everyday Good Deeds

Updated Category News Views 375

Understanding Kindness and Its Impact For educators and students, kindness is a fundamental value that shapes everyday interactions. Malik Singleton, a student support coordinator at a partner school, believes that even small acts of kindness can leave a lasting impression on individuals and the community. Although we celebrate kindness on specific days, its essence is...

Continue Reading